EP-1255: SABR and FDG-PET in lung cancer: a SUV cut-off value before treatment to predict local control.  by Vagge, S. et al.
ESTRO 35 2016                                                                                                                                                    S593 
________________________________________________________________________________ 
clinical or radiological pneumonitis did not reach statistical 
significance (P<0.05). 
 
 
 
Conclusion: SABR for primary lung cancer performed at the 
Leeds Cancer Centre continues to show excellent local 
control rates, with low toxicity and has comparable overall 5-
year survival rates to other published series. Poorer 
performance status and larger tumour size were associated 
with a negative effect on overall survival. 
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Purpose or Objective: To investigate the prognostic value of 
[(18)F] fluorodeoxyglucose positron emission tomography 
(FDG-PET) uptake before stereotactic ablative radiotherapy 
(SABR) for stage I non-small-cell lung cancer (NSCLC). 
 
Material and Methods: From August 2009 to December 2014, 
80 medically inoperable patients with proven Stage I NSCLC 
or FDG-PET-positive primary lung tumors were analyzed 
retrospectively. SABR consisted of 48-50 Gy delivered in 4 to 
5 fractions, respectively by two or one fraction per week. 
Maximum standardized uptake value (SUV (max)) of the 
treated lesion was assessed before SABR. Patients were 
subsequently followed at regular intervals using computed 
tomography (CT) and FDG-PET scans. Association between 
post-SABR SUV (max, at minimum of 12 weeks after 
treatment) and local control (LC), overall survival (OS) was 
examined. 
 
Results: Median follow-up time was 20 months (range, 9-55 
months). Median lesion size was 20 mm (range, 8-50 mm). 
Due to statistical evaluations around the median range of SUV 
(max), a pre SABR SUV (max) 5.0 was selected as a cut-off to 
analyze LC and OS. The 2-year LC was 61.2% versus 78.7% for 
higher or equal than 5.0 versus lower than 5.0 SUV (max), 
yielding an adjusted sub-hazard ratio (SHR) for high pre SABR 
SUV (max) of 5.3 (95% confidence interval [CI], 1.3-25.5; p = 
0.057). Two-year OS was 80.6% versus 76.6% respectively 
(hazard ratio [HR], 1.4; 95%; p = 0.46). No differences were 
observed between fractionation schedules or different tumor 
volumes. 
 
 
 
Conclusion: FDG uptake (SUV (max) ≥5.0) before SABR 
signifies reduces risk of local failure. These results from 
single institution might stimulate a large accrual from 
multicenter prospective analysis, due to controversial results 
already published. 
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Purpose or Objective: To report our initial experience in 
stereotactic body radiation therapy (SBRT) delivered using 
RapidArc (RA) technique with or without flattening filter 
beam in terms of toxicity and clinical outcomes. 
 
Material and Methods: From September 2013 to September 
2015, 16 consecutive patients with 27 metastatic hepatic 
lesions were treated with SBRT in a TrueBeam unit using RA 
technique. 6 lesions received a Volumetric Modulated Arc 
Therapy (VMAT) treatment using 6Mv RA with flattening filter 
and 21 were treated without flattening filter (flattening filter 
free beam- FFF) with an energy of 10Mv. GTV was defined 
using multi-phase CT scans, PET/CT and/or MRI. The lesions 
were marked with a radiopaque coil to localize them in the 
verification CBCT (ConeBeamCT) that was performed daily. 
ITV (internal target volume) was calculated in gated modality 
with internal coil tracking by 2D imaging. Prescribed doses 
ranged from 30-60Gy in 3-5 fractions to ITV. The dose was 
downscaled in cases of not full achievement of dose 
constraints. 99.5% of the target volume was covered by 100% 
of the prescription dose. Initially, we followed the 
constraints proposed by Timmerman: Three fractions 
constraints for organs at risk were: 700cc of liver free from 
the 17.1Gy isodose, Dmax< 24Gy for stomach and duodenum, 
D5cc< 15Gy for duodenum, Dmax< 30Gy for heart, D1.2cc< 
11Gy and D0.25Gy< 18Gy for spinal cord. Five fractions 
constraints for organs at risk were: 700cc of liver free from 
the 21Gy isodose, Dmax< 32Gy for stomach and duodenum, 
D5cc< 18Gy for duodenum, Dmax< 38Gy for heart, D1.2cc< 
13.5Gy and D0.25Gy< 22.5Gy for spinal cord. Nowadays we 
are following the constraints proposed by the Spanish Society 
of Radiation Oncology: Liver: 700cc of liver free from the 
15Gy isodose, V21<30%, V15<20Gy, Mean dose: <15Gy for 
three fractions and <20Gy for five fractions; D5cc<15Gy for 
duodenum; V30<1cc and V21<5cc for heart; Dmax<18Gy for 
spinal cord. 
 
Results: Mean age of the patients was 59 years and the mean 
following time since the end of SBRT was 9.14 months. ITV 
mean volume was 41.78cc. The most frequent side effect was 
acute asthenia and we identified two cases of asymptomatic 
increase in liver enzymes. No patient experienced acute 
toxicity greater than Grade 2. In relation to the local 
response, we used RECIST and/or PERCIST criteria to 
reevaluate the lesions. We found 15 complete and 1 partial 
responses, 1 progression, 5 stable lesions and 2 pseudo 
progressions. 2 patients (4 lesions) were lost in the long-term 
clinical follow up. No differences between both treatment 
modalities (with or without FF) were found in terms of local 
control or side effects (either acute or chronic). 
 
Conclusion: SBRT for liver targets delivered by means of 
RapidArc resulted to be a feasible technique, with few side 
effects and good rates of local response in metastatic liver 
targets. 
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